Best Nanotechnology Stocks To Keep An Eye On – April 19th

by · The Cerbat Gem

OSI Systems, NVE, Biodexa Pharmaceuticals, Clene, Virpax Pharmaceuticals, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks are shares of companies that research, develop, or manufacture products using materials and devices engineered at the nanoscale. These companies often span multiple industries—such as electronics, healthcare, and materials science—and are considered potential drivers of innovation due to the transformative applications of nanotechnology. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

Shares of NASDAQ OSIS traded up $4.84 during midday trading on Friday, reaching $194.19. The stock had a trading volume of 249,990 shares, compared to its average volume of 184,684. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.25 and a current ratio of 1.88. OSI Systems has a 12-month low of $126.57 and a 12-month high of $220.00. The stock has a 50-day moving average of $194.28 and a 200-day moving average of $175.70. The company has a market capitalization of $3.26 billion, a price-to-earnings ratio of 24.99, a price-to-earnings-growth ratio of 1.81 and a beta of 1.19.

Read Our Latest Research Report on OSIS

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

NVEC stock traded up $0.12 during trading on Friday, reaching $57.09. The company’s stock had a trading volume of 27,121 shares, compared to its average volume of 22,259. The company’s fifty day moving average is $65.16 and its 200-day moving average is $73.54. NVE has a 1 year low of $51.50 and a 1 year high of $89.98. The company has a market capitalization of $276.14 million, a P/E ratio of 18.42 and a beta of 1.05.

Read Our Latest Research Report on NVEC

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

BDRX traded down $0.03 on Friday, hitting $1.43. 83,028 shares of the company’s stock traded hands, compared to its average volume of 594,829. Biodexa Pharmaceuticals has a one year low of $1.14 and a one year high of $74.00. The company’s 50 day simple moving average is $2.41 and its 200-day simple moving average is $4.00.

Read Our Latest Research Report on BDRX

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

CLNN traded down $0.02 during trading on Friday, hitting $3.00. 15,345 shares of the company traded hands, compared to its average volume of 75,745. The company has a market cap of $25.79 million, a PE ratio of -0.57 and a beta of 0.46. Clene has a 1 year low of $2.57 and a 1 year high of $9.20. The stock’s 50-day simple moving average is $3.85 and its two-hundred day simple moving average is $4.59.

Read Our Latest Research Report on CLNN

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

Shares of Virpax Pharmaceuticals stock traded up $0.05 during trading on Friday, reaching $0.26. 18,174 shares of the stock traded hands, compared to its average volume of 200,808. Virpax Pharmaceuticals has a 52-week low of $0.13 and a 52-week high of $98.74. The business has a fifty day simple moving average of $3.31 and a two-hundred day simple moving average of $8.71.

Read Our Latest Research Report on VRPX

Clene (CLNNW)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

CLNNW remained flat at $0.03 during trading hours on Friday. 1,344 shares of the company traded hands, compared to its average volume of 12,470. Clene has a 12 month low of $0.02 and a 12 month high of $0.08. The firm has a 50 day moving average of $0.04 and a 200-day moving average of $0.04.

Read Our Latest Research Report on CLNNW

See Also